Medical devices, healthcare technology and the business of care
510(k) clearance · K253173

uCT 780 with uWS-CT-Dual Energy Analysis

Shanghai United Imaging Healthcare Co., Ltd. · Decision date Jan 20, 2026

FDA DECISIONK253173

What did the FDA decide?

FDA records K253173 as a 510(k) premarket notification, with a decision dated Jan 20, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Jan 20, 2026

FDA source record

Regulatory record facts

Identifier
K253173
Regulatory pathway
510(k) premarket notification
Product code
JAK
Decision code
SESE
Decision date
Jan 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, X-Ray, Tomography, Computed.

Product code
JAK
FDA device class
2

FDA decision timeline

  1. K253173 received

    Application receipt date recorded by FDA.

  2. K253173 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code JAK

Product / regulatory recordCompanyPathwayDecision dateSource
Coreline Soft Co., Ltd.510(k) clearanceOct 16, 2026FDA
CAS-One IRK261225
Cascination AG510(k) clearanceSep 29, 2026FDA
Samsung HME America, Inc., dba NeuroLogica Corp.510(k) clearanceSep 22, 2026FDA
Fujifilm Corporation510(k) clearanceSep 18, 2026FDA
Fujifilm Corporation510(k) clearanceSep 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Shanghai United Imaging Healthcare Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Shanghai

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records